Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-06-12

Clinical Trial Update: Pembrolizumab in Metastatic Anal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab in metastatic anal cancer completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Anal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-06-12